Press release
Autism Spectrum Disorder Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
DelveInsight's, "Autism Spectrum Disorder Pipeline Insight, 2025" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Autism Spectrum Disorder pipeline landscape. It covers the Autism Spectrum Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, clinical stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Explore our latest breakthroughs in Autism Spectrum Disorder Research. Learn more about our innovative pipeline today! @ Autism Spectrum Disorder Pipeline Outlook- https://www.delveinsight.com/sample-request/autism-spectrum-disorder-asd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Autism Spectrum Disorder Pipeline Report
• In July 2025, Intra-Cellular Therapies, Inc. conducted a study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
• DelveInsight's Autism Spectrum Disorder pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Autism Spectrum Disorder treatment.
• The leading Autism Spectrum Disorder Companies such as Astrogen, MapLight Therapeutics, Axial Therapeutics, Aardvark Therapeutics, Ajna BioSciences, Intra-Cellular Therapies, Finch Therapeutics Group, PharmAla Biotech and others.
• Promising Autism Spectrum Disorder Pipeline Therapies such as ML-004, Arbaclofen, Arbaclofen, L1-79, Cariprazine, Cannabidivarin, RG7314, GWP42003-P, Suramin Sodium and others
Stay informed about the cutting-edge advancements in Autism Spectrum Disorder treatments. Download for updates and be a part of the revolution in Genetic Disease Care @ Autism Spectrum Disorder Clinical Trials Assessment- https://www.delveinsight.com/sample-request/autism-spectrum-disorder-asd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Autism Spectrum Disorder Emerging Drugs Profile
• AST-001: Astrogen
AST-001 is a small-molecule drug developed by Astrogen to treat Autism Spectrum Disorder. AST-001 functions as an L-isomer of serine, which plays a critical role in various neurological processes. It has been shown to improve social deficits and restore dopamine neuron activity in preclinical models of ASD. The drug enhances dopamine neuron firing through the normalization of specific ion channel activities, suggesting its potential as a therapeutic agent for improving social interaction and cognitive function in patients with ASD. It targets neurological mechanisms to improve core symptoms in ASD patients and has advanced to Phase III clinical trials following regulatory approval in South Korea.
• ML004: MapLight Therapeutics
ML-004 is MapLight's lead clinical compound. Its selective pharmacological properties of make it a highly specific therapy with limited side effects. The company is developing ML-004 for multiple indications, including sociability and irritability in ASD and agitation and aggression in Alzheimer's disease. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Autism Spectrum Disorder.
• AJA001: Ajna BioSciences
AJA001 is a full-spectrum formulation derived from sativa, designed specifically for Autism Spectrum Disorder (ASD). Created through DEFLORIA LLC, a joint venture between Ajna, Charlotte's Web, and BAT, it aims to be the first FDA-approved botanical hemp extract for ASD. Leveraging Charlotte's Web's patented genetics, AJA001 optimizes bioavailability, showing promising symptom relief and quality-of-life improvements in early clinical trials.
The Autism Spectrum Disorder Pipeline Report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Autism Spectrum Disorder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Autism Spectrum Disorder Treatment.
• Autism Spectrum Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Autism Spectrum Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Autism Spectrum Disorder market.
Learn more about Autism Spectrum Disorder Drugs opportunities in our groundbreaking Autism Spectrum Disorder research and development projects @ Autism Spectrum Disorder Unmet Needs- https://www.delveinsight.com/sample-request/autism-spectrum-disorder-asd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Autism Spectrum Disorder Companies
Astrogen, MapLight Therapeutics, Axial Therapeutics, Aardvark Therapeutics, Ajna BioSciences, Intra-Cellular Therapies, Finch Therapeutics Group, PharmAla Biotech and others.
Autism Spectrum Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Autism Spectrum Disorder Products have been categorized under various Molecule types such as,
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Discover the latest advancements in Autism Spectrum Disorder treatment by visiting our website. Stay informed about how we're transforming the future of Genetic Disease @ Autism Spectrum Disorder Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/autism-spectrum-disorder-asd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Autism Spectrum Disorder Pipeline Report
• Coverage- Global
• Autism Spectrum Disorder Companies- Astrogen, MapLight Therapeutics, Axial Therapeutics, Aardvark Therapeutics, Ajna BioSciences, Intra-Cellular Therapies, Finch Therapeutics Group, PharmAla Biotech and others.
• Autism Spectrum Disorder Therapies- ML-004, Arbaclofen, Arbaclofen, L1-79, Cariprazine, Cannabidivarin, RG7314, GWP42003-P, Suramin Sodium and others.
• Autism Spectrum Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Autism Spectrum Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Autism Spectrum Disorder Pipeline on our website @ Autism Spectrum Disorder Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/autism-spectrum-disorder-asd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Contents
1. Introduction
2. Executive Summary
3. Autism Spectrum Disorder: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Autism Spectrum Disorder- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. AST-001: Astrogen
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. ML004: MapLight Therapeutics
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. AJA001: Ajna BioSciences
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Autism Spectrum Disorder Key Companies
21. Autism Spectrum Disorder Key Products
22. Autism Spectrum Disorder- Unmet Needs
23. Autism Spectrum Disorder- Market Drivers and Barriers
24. Autism Spectrum Disorder- Future Perspectives and Conclusion
25. Autism Spectrum Disorder Analyst Views
26. Autism Spectrum Disorder Key Companies
27. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Autism Spectrum Disorder Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4106795 • Views: …
More Releases from DelveInsight Business Research LLP

Familial Adenomatous Polyposis Pipeline Appears Robust With 4+ Key Pharma Compan …
"DelveInsight's, "Familial adenomatous polyposis Pipeline Insight, 2025" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Familial adenomatous polyposis pipeline landscape. It covers the Familial Adenomatous Polyposis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Familial Adenomatous Polyposis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…

Cushing Syndrome Pipeline Appears Robust With 4+ Key Pharma Companies Actively W …
DelveInsight's, "Cushing Syndrome Pipeline Insight, 2025" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Cushing Syndrome pipeline landscape. It covers the Cushing Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cushing Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Cushing Syndrome…

Acute Graft-versus-Host Disease Pipeline 2025: Groundbreaking Clinical Advanceme …
With Acute Graft-versus-Host Disease reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Acute Graft-versus-Host Disease pipeline comprises 4+ pharmaceutical and biotech companies actively developing 6+ therapeutic candidates targeting Acute Graft-versus-Host Disease. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation…

Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline 2025: Groundbreaking …
With Chemotherapy Induced Peripheral Neuropathy (CIPN) reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline comprises 4+ pharmaceutical and biotech companies actively developing 5+ therapeutic candidates targeting Chemotherapy Induced Peripheral Neuropathy (CIPN). These therapies span various stages of clinical and…
More Releases for Autism
Autism Awareness Jewellery Collection
House of Silver, an online jewellery shop for Sterling silver jewellery, is pleased to announce its exclusive Autism Awareness Jewellery Collection.
Autism is a major part of many people's lives and House of Silver is excited to be able to participate in spreading awareness and acceptance of it. An inclusive employer with autistic staff, House of Silver is a family-run business with many personal and professional experiences with autism and autistic…
Autism-Pipeline Review H1 2018
Pharmaceutical and Healthcare disease pipeline guide Autism-Pipeline Review, H1 2018, provides an overview of the Autism (Central Nervous System) pipeline landscape.
Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child's sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.
Report Highlights
Publisher's Pharmaceutical…
Autism-Pipeline Review H2 2017
ReportsWeb.com published “Autism” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Autism-Pipeline Review H2 2017 provides an overview of the Autism (Central Nervous System) pipeline landscape.
Autism also known as complex developmental disability is a neurodevelopment disorder characterized by social interaction…
Autism-Pipeline Review H2 2017
ReportsWeb.com published “Autism” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Autism-Pipeline Review H2 2017 provides an overview of the Autism (Central Nervous System) pipeline landscape.
Autism also known as complex developmental disability is a neurodevelopment disorder characterized by social interaction…
Autism Education Services Offers New Autism Programs and Training to Schools Nat …
Autism Education Services (Autism EDS) is now offering comprehensive autism programs and services, autism behavior management strategies and full staff training to schools nationwide in an effort to create and share custom autism program development for children with autism. The new programming implemented by Autism EDS has exhibited great success in school districts in California and Colorado, where the amount of adult support required has decreased for over 90% of…
Autism Podcast released for Autism Sunday
AUTISM PODCAST RELEASED by Midnight in Chicago
FOR AUTISM SUNDAY on February 8, 2009
Peterborough, ON: Thomas D. Taylor and Peterborough based MIDNIGHT IN CHICAGO have released their most recent free audio podcast on Autism entitled “Why Is There Autism: A Christian Perspective” to coincide with Autism Sunday on February 8.
“As a Christian, it’s important for me to help others better understand what the Bible says about differences such as Autism,”…